Dr. Graham serves as deputy director of the Vaccine Research Center (VRC, in parallel with Dr. Richard Koup) and assists the director in establishing and focusing the scientific direction for the VRC as a premier intramural research organization. He provides direction and oversight of VRC-sponsored clinical trials by providing expert clinical advice regarding the design, planning, and execution of clinical trials. In addition, he is chief of the Viral Pathogenesis Laboratory and the associated Translational Science Core.
Dr. Graham is an immunologist, virologist, and clinical trials physician whose primary interests are viral pathogenesis, immunity, and vaccine development. His work is focused on HIV, respiratory syncytial virus (RSV), and emerging viral diseases. He has been involved in the clinical evaluation of candidate HIV vaccines for more than 25 years and has an ongoing interest in science education and expanding research opportunities for under-represented minorities.
After graduating from Rice University in 1975, he obtained his medical degree from the University of Kansas School of Medicine in 1979. From 1979 to 1984 he served as intern, resident, and chief resident in internal medicine and from 1984 to 1986 was a clinical fellow in infectious diseases. He earned a PhD in microbiology and immunology at Vanderbilt University School of Medicine in 1991 and then rose to the rank of professor of medicine with a joint appointment in the department of microbiology and immunology. In 2000, Dr. Graham was recruited as one of the founding investigators for the VRC and joined as chief of the Viral Pathogenesis Laboratory and Clinical Trials Core.
Barney S. Graham, MD, PhD Presentations
June 18, 2020 at 10:00 AM - 11:15 AM
The spread of SARS-CoV-2 and the resulting COVID-19 pandemic has had wide-reaching effects that require a multifaceted response. Accelerating vaccine development and distribution is a key component in responding to this emerging pathogen. Vaccine development typically takes decades from research and development to implementation, so having licensed and approved vaccines available for mass distribution in a 12-18 month timeframe would...